Deferred Tax Assets, Operating Loss Carryforwards of Nurix Therapeutics, Inc. from 30 Nov 2019 to 30 Nov 2025

Taxonomy & unit: us-gaap: USD
Description: Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Summary: Nurix Therapeutics, Inc. quarterly Deferred Tax Assets, Operating Loss Carryforwards in USD history and change rate from 30 Nov 2019 to 30 Nov 2025.
Nurix Therapeutics, Inc. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending 30 Nov 2025 was $106,447,000, a 16% increase year-over-year.
Source SEC data: View on sec.gov

Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)

Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Change (%)

Nurix Therapeutics, Inc. Quarterly Deferred Tax Assets, Operating Loss Carryforwards (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q4 2025	$106,447,000	+$14,661,000	+16%	30 Nov 2025	10-K	28 Jan 2026	2025	FY
Q4 2024	$91,786,000	-$345,000	-0.37%	30 Nov 2024	10-K	28 Jan 2026	2025	FY
Q4 2023	$92,131,000	+$8,356,000	+10%	30 Nov 2023	10-K	28 Jan 2025	2024	FY
Q4 2022	$83,775,000	+$42,694,000	+104%	30 Nov 2022	10-K	15 Feb 2024	2023	FY
Q4 2021	$41,081,000	+$15,936,000	+63%	30 Nov 2021	10-K	09 Feb 2023	2022	FY
Q4 2020	$25,145,000	-$6,388,000	-20%	30 Nov 2020	10-K	28 Jan 2022	2021	FY
Q4 2019	$31,533,000			30 Nov 2019	10-K	16 Feb 2021	2020	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.